CDKN2C and Huntington disease: p-value = 0.0024), together with older age (equal or over 65 years), ISS stage III, and distinct molecular variables such as del(1p)/CDKN2C, del(13q)/RB1, and 1q gain/amplification alone or in combination with TP53 alterations; on the contrary, ISS stage I and HD cases showed a 69% and 36% death risk reduction, respectively (Supplementary Figure S2).